About this Research Topic
The IL-17 cytokine family represents a wide class of pleiotropic inflammatory molecules that are structurally related. Historically the most well-known cytokines across the IL-17 family are the IL-17A, IL-17F and IL-17E (also known as IL-25) while others such as IL-17B, IL-17C or IL-17D are emerging in modulating tissue homeostasis and disease. This cytokine family activates downstream signaling through the IL-17 receptor (IL-17R) family, which includes five members named IL-17receptor(R)A, IL-17RB, IL-17RC, IL-17RE and IL-17RD. In this context, IL-17RA can play a pleiotropic role by interacting with other IL17 receptors, including IL-17RC, IL-17RB, IL-17RE and IL-17RD. Increasing evidence indicates that the IL-17 cytokines family and their receptors have a dual key role. On one hand, they play a role in tissue homeostasis and mucosal defense, while on the other hand, they play a role in different diseases including autoimmunity, chronic immune-mediated diseases and tumor immunology.
The IL-17 cytokines and receptors are expressed by a wide range of stromal and immune cells including epithelia, endothelia, fibroblasts, macrophages, neutrophils, T-helper 2 and 17, CD8+ T, T regulatory, natural killer (NK) and group 2 and 3 innate lymphoid cells.
IL-17A and IL-17F are mainly associated to type-17 response and act as pro-inflammatory molecules in several compartments such as in the gut, central nervous system, lung or skin. Both IL-17A and IL-17F cytokines can mediate pathways activated through IL-17RA/IL-17RC heterodimers. Recently, it has been proposed that IL-17A can modulate inflammation through the IL-17RA/IL-17RD receptor complex. IL-17E (IL-25) and IL-17B are known to mediate signaling related to type 2 immunity and the IL-17RA/IL-17RB heterodimers are required for down-stream signaling activation. In addition, IL17C is often associated with the mucosal host defense and is recognized by IL17RE that synergistically acts as a heterodimer with the IL-17RA.
Overall, the IL-17 cytokine family displays organ-specific inflammatory responses in several pathophysiological conditions: in the gut, skin, pancreas, spleen, liver, nervous and respiratory system as well as in cancer development. In this context, the IL-17 cytokines can modulate complex dynamic interactions between stromal and immune cells and determine the outcome of pathophysiological processes. Therefore, further efforts in the field of immunity, host-pathogen interactions and tumor immunology are required to shed light on the multifaceted IL-17 cytokines role.
In this Research Topic, we invite scientists to contribute with Reviews, Mini-Reviews and Original Research articles that will help the field to a better comprehension of the biological mechanisms mediated by the IL-17 cytokine family in health and disease. We welcome manuscripts focusing on, but not limited to, the following topics:
● Molecular and cellular mechanisms of IL-17 cytokines in health and disease.
● The emerging contribution of IL-17 cytokines in pathophysiological conditions such as autoimmunity, chronic immune-mediated diseases, and tumor immunology.
● Development of diagnostics, vaccines, and treatments targeting pathways mediated by IL-17 family members, including basic and translational research studies related to innovative pharmacological approaches.
The IL-17 cytokines and receptors are expressed by a wide range of stromal and immune cells including epithelia, endothelia, fibroblasts, macrophages, neutrophils, T-helper 2 and 17, CD8+ T, T regulatory, natural killer (NK) and group 2 and 3 innate lymphoid cells.
IL-17A and IL-17F are mainly associated to type-17 response and act as pro-inflammatory molecules in several compartments such as in the gut, central nervous system, lung or skin. Both IL-17A and IL-17F cytokines can mediate pathways activated through IL-17RA/IL-17RC heterodimers. Recently, it has been proposed that IL-17A can modulate inflammation through the IL-17RA/IL-17RD receptor complex. IL-17E (IL-25) and IL-17B are known to mediate signaling related to type 2 immunity and the IL-17RA/IL-17RB heterodimers are required for down-stream signaling activation. In addition, IL17C is often associated with the mucosal host defense and is recognized by IL17RE that synergistically acts as a heterodimer with the IL-17RA.
Overall, the IL-17 cytokine family displays organ-specific inflammatory responses in several pathophysiological conditions: in the gut, skin, pancreas, spleen, liver, nervous and respiratory system as well as in cancer development. In this context, the IL-17 cytokines can modulate complex dynamic interactions between stromal and immune cells and determine the outcome of pathophysiological processes. Therefore, further efforts in the field of immunity, host-pathogen interactions and tumor immunology are required to shed light on the multifaceted IL-17 cytokines role.
In this Research Topic, we invite scientists to contribute with Reviews, Mini-Reviews and Original Research articles that will help the field to a better comprehension of the biological mechanisms mediated by the IL-17 cytokine family in health and disease. We welcome manuscripts focusing on, but not limited to, the following topics:
● Molecular and cellular mechanisms of IL-17 cytokines in health and disease.
● The emerging contribution of IL-17 cytokines in pathophysiological conditions such as autoimmunity, chronic immune-mediated diseases, and tumor immunology.
● Development of diagnostics, vaccines, and treatments targeting pathways mediated by IL-17 family members, including basic and translational research studies related to innovative pharmacological approaches.
Keywords: IL-17 cytokine family, IL-17 driven disease, IL-17 signal transduction, IL-17 therapeutics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
